4 December 2017 - HAS has posted the agenda for the next scheduled TC meeting.

The Transparency Commission will consider the reimbursement of:

• Ticagrelor (Brilique)
  
• Vedolizumab (Entyvio)
  
• Carfilzomib (Kyprolis)
  
• Epoetin alfa (Eprex)
  
• Immunoglobulin (human) (Clairyg)
  
• Tenofovir disoproxil fumarate with emtricitabine (Truvada)
  
• Insulin degludec with liraglutide (Xultophy)
  

Read TC agenda [French]